Platelet Dysfunction Due to Aspirin
Conditions
Keywords
platelets, phospholipids, aspirin
Brief summary
Healthy volunteers (n = 28) were recruited from the workplace (14 male, 14 female; age range 20-50 years). Ethical approval, which included informed consent, was from Cardiff University, Schools of Medicine and Dentistry Research Ethics Committee (SMREC16/02). Following a 2-week period free from non-steroidal anti-inflammatory drugs (NSAIDs), peripheral blood was obtained and platelets isolated. Participants were commenced on aspirin 75 mg once daily for seven days and then provided a repeat blood sample. Following a 2-month period, participants were invited to repeat samples pre- and post-aspirin, and again a third time 2 months later.
Interventions
DRUGAspirin
1 week of aspirin supplementation prior to sampling
Sponsors
Cardiff University
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* two-week washout period from any non-steroidal anti-inflammatory drugs (NSAIDs) use. * Ability to take aspirin 75 mg once daily for seven days and sampled thereafter, before stopping the aspirin. * Willingness to repeat this process after two months and four months of the initial sampling date.
Exclusion criteria
\* Recent NSAID use
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Platelet EoxPL differences in amounts (ng) as measured by liquid chromatography with tandem mass spectrometry | 4 months | Samples on and off aspirin will be quantified for the 47 most common eoxPL species (as described by Slatter et al, Cell Metabolism 23, 930-944, May 10, 2016) using established liquid chromatography with tandem mass spectrometry (LC-MS/MS). Differences in amounts on and off aspirin will be quantified and tested for statistical significance. |
Countries
United Kingdom
Outcome results
None listed